First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research

First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research

Federica Tomao,1 Serena Maria Boccia,2 Carolina Maria Sassu,2 Martina Chirra,3 Innocenza Palaia,2 Maria Cristina Petrella,4 Violante Di Donato,2 Nicoletta Colombo,1,5 Pierluigi Benedetti Panici2 1Department of Gynecologic Oncology, European Institute of Oncology (IEO) IRCCS, Milan, Italy; 2Departmen...

Full description

Bibliographic Details
Main Authors: Tomao F, Boccia SM, Sassu CM, Chirra M, Palaia I, Petrella MC, Di Donato V, Colombo N, Benedetti Panici P
Format: Article
Language:English
Published: Dove Medical Press 2020-07-01
Series:Cancer Management and Research
Subjects:
newly diagnosed ovarian cancer
early stage ovarian cancer
olaparib
parpinhibitors
brca mutation.
Online Access:https://www.dovepress.com/first-line-treatment-nbspwith-olaparibnbspfor-early-stage-brca-positiv-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/first-line-treatment-nbspwith-olaparibnbspfor-early-stage-brca-positiv-peer-reviewed-article-CMAR

Similar Items